



Technical Memorandum

TO: Physicians and Clinical Staff

From: Dr. Matthew J. Bankowski, PhD, D(ABMM)
V.P. – Director, Clinical and Molecular Microbiology and Infectious Disease

Dr. Wesley Kim, MD
Medical Director

Date: May 4, 2010

Subject: Herpes Simplex Virus (HSV-1 and HSV-2), IgG

Effective May 10, 2010, HSV testing will be offered at Central Core Lab on the BioPlex 2200 System, an automated testing platform.

Test Information:

Analyte	New Unit Codes
Herpes Simplex Type 1 Ab, IgG	39011
Herpes Simplex Type 2 Ab, IgG	39001
Herpes Simplex Type 1 and 2 Ab, IgG	46871

Specimen Requirements:

Serum 1.0 mL, SST

Test Frequency:

3 day(s) per week

Interpretive Guide: The numerical values for the cutoff/interpretation will be provided as shown below:

Interpretation of Results for HSV-1 IgG

AI (Antibody Index)	Result	Interpretation
<0.9	Negative	No HSV-1 IgG antibodies detected. Patient is presumed not to have had a previous HSV-1 infection.
0.9 – 1.0	Equivocal	Equivocal results. Obtain an additional sample for re-testing
≥ 1.1	Positive	IgG antibody to HSV-1 detected.

Interpretation of Results for HSV-2 IgG

AI (Antibody Index)	Result	Interpretation
<0.9	Negative	No HSV-2 IgG antibodies detected. Patient is presumed not to have had a previous HSV-2 infection.
0.9 – 1.0	Equivocal	Equivocal results. Obtain an additional sample for re-testing
≥ 1.1	Positive	IgG antibody to HSV-2 detected.

NOTE: Antibody Index (AI) values reflect qualitative changes in antibody concentration that cannot be directly associated with a clinical condition or disease state.

Please contact Dr. Matthew Bankowski, Ph.D., Director, Clinical and Molecular Microbiology and Infectious Disease with any questions at 589-5242.